{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T20:33:43Z","timestamp":1770496423301,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jvacx.2023.100403","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T20:29:31Z","timestamp":1699043371000},"page":"100403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Crosslinked chitosan microparticles as a safe and efficient DNA carrier for intranasal vaccination against cutaneous leishmaniasis"],"prefix":"10.1016","volume":"15","author":[{"given":"Beatriz L.S.","family":"Costa Souza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7242-4206","authenticated-orcid":false,"given":"Eduardo F.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabella P.S.","family":"Bezerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel C.O.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria B.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria In\u00eas","family":"R\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert L.","family":"de Matos Guedes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartira","family":"Rossi-Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jvacx.2023.100403_b0005","doi-asserted-by":"crossref","first-page":"e22478","DOI":"10.2196\/22478","article-title":"Mobile health strategies to tackle skin neglected tropical diseases with recommendations from innovative experiences: Systematic review","volume":"8","author":"Carrion","year":"2020","journal-title":"JMIR Mhealth Uhealth"},{"issue":"12","key":"10.1016\/j.jvacx.2023.100403_b0010","doi-asserted-by":"crossref","first-page":"e0006052","DOI":"10.1371\/journal.pntd.0006052","article-title":"Drug resistance and treatment failure in leishmaniasis: A 21st century challenge","volume":"11","author":"Ponte-Sucre","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"10.1016\/j.jvacx.2023.100403_b0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/14760584.2018.1459191","article-title":"Vaccine candidates against leishmania under current research","volume":"17","author":"Iborra","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jvacx.2023.100403_b0020","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.chom.2020.03.011","article-title":"Th1-Th2 Cross-Regulation Controls Early Leishmania Infection in the Skin by Modulating the Size of the Permissive Monocytic Host Cell Reservoir","volume":"27","author":"Carneiro","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"7","key":"10.1016\/j.jvacx.2023.100403_b0025","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1590\/S0100-879X2005000700001","article-title":"What about Th1\/Th2 in cutaneous leishmaniasis vaccine discovery?","volume":"38","author":"Campos-Neto","year":"2005","journal-title":"Braz J Med Biol Res"},{"issue":"5286","key":"10.1016\/j.jvacx.2023.100403_b0030","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1126\/science.274.5286.421","article-title":"Resistance to Leishmania major induced by tolerance to a single antigen","volume":"274","author":"Julia","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.jvacx.2023.100403_b0035","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1128\/IAI.72.8.4521-4527.2004","article-title":"Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK","author":"Pinto","year":"2004","journal-title":"Infect Immun"},{"issue":"14","key":"10.1016\/j.jvacx.2023.100403_b0040","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1016\/j.vaccine.2006.05.093","article-title":"Protection against cutaneous leishmaniasis by intranasal vaccination with lipophosphoglycan","volume":"25","author":"Pinheiro","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2023.100403_b0045","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.vaccine.2006.11.060","article-title":"Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice","volume":"25","author":"Gomes","year":"2007","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.jvacx.2023.100403_b0050","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1017\/S0031182011001417","article-title":"Intranasal immunization with LACK-DNA promotes protective immunity in hamsters challenged with Leishmania chagasi","volume":"138","author":"Gomes","year":"2011","journal-title":"Parasitology"},{"key":"10.1016\/j.jvacx.2023.100403_b0055","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1186\/1756-3305-7-448","article-title":"Intranasal vaccination with extracellular serine proteases of Leishmania amazonensis confers protective immunity to BALB\/c mice against infection","volume":"7","author":"de Matos Guedes","year":"2014","journal-title":"Parasit Vectors"},{"issue":"13","key":"10.1016\/j.jvacx.2023.100403_b0060","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1017\/S0031182015001250","article-title":"Intranasal vaccination with killed Leishmania amazonensis promastigotes antigen (LaAg) associated with CAF01 adjuvant induces partial protection in BALB\/c mice challenged with Leishmania (infantum) chagasi","volume":"142","author":"Leal","year":"2015","journal-title":"Parasitology"},{"issue":"1","key":"10.1016\/j.jvacx.2023.100403_b0065","doi-asserted-by":"crossref","first-page":"e3439","DOI":"10.1371\/journal.pntd.0003439","article-title":"Intranasal vaccination with leishmanial antigen protects golden hamster (Mesocricetus auratus) against Leishmania (Viannia) braziliensis infection","volume":"9","author":"Da Silva-Couto","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"10.1016\/j.jvacx.2023.100403_b0070","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s13071-016-1822-9","article-title":"Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57Bl\/6 mice","volume":"9","author":"Pratti","year":"2016","journal-title":"Parasit Vectors"},{"issue":"18","key":"10.1016\/j.jvacx.2023.100403_b0075","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1016\/j.vaccine.2018.03.020","article-title":"Intranasal but not subcutaneous vaccination with LaAg allows rapid expansion of protective immunity against cutaneous leishmaniasis","volume":"36","author":"Pereira Silva Bezerra","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jvacx.2023.100403_b0080","doi-asserted-by":"crossref","first-page":"e0007146","DOI":"10.1371\/journal.pntd.0007146","article-title":"The role of TLR9 on Leishmania amazonensis infection and its influence on intranasal LaAg vaccine efficacy","volume":"13","author":"Pratti","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"issue":"25\u201326","key":"10.1016\/j.jvacx.2023.100403_b0085","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1016\/S0264-410X(03)00427-4","article-title":"Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB\/c and C57BL\/6 mice against cutaneous leishmaniasis","volume":"21","author":"Pinto","year":"2003","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.jvacx.2023.100403_b0090","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.micinf.2005.04.016","article-title":"TGF-beta-associated enhanced susceptibility to leishmaniasis following intramuscular vaccination of mice with Leishmania amazonensis antigens","volume":"7","author":"Pinheiro","year":"2005","journal-title":"Microbes Infect"},{"issue":"1","key":"10.1016\/j.jvacx.2023.100403_b0095","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00436-005-0008-8","article-title":"Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-gamma production but does not protect BALB\/c mice against Leishmania chagasi intravenous challenge","volume":"98","author":"Marques-da-Silva","year":"2005","journal-title":"Parasitol Res"},{"issue":"2","key":"10.1016\/j.jvacx.2023.100403_b0100","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.it.2017.10.002","article-title":"Improving Vaccine and Immunotherapy Design Using Biomaterials","volume":"39","author":"Bookstaver","year":"2018","journal-title":"Trends Immunol"},{"issue":"9","key":"10.1016\/j.jvacx.2023.100403_b0105","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.addr.2013.07.005","article-title":"Chitosans for delivery of nucleic acids","volume":"65","author":"Buschmann","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jvacx.2023.100403_b0110","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ijbiomac.2016.05.054","article-title":"Why Chitosan? From properties to perspective of mucosal drug delivery","volume":"91","author":"Kumar","year":"2016","journal-title":"Int J Biol Macromol"},{"issue":"10","key":"10.1016\/j.jvacx.2023.100403_b0115","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3390\/molecules24101960","article-title":"Chitosan-based (Nano)materials for Novel Biomedical Applications","volume":"24","author":"Kravanja","year":"2019","journal-title":"Molecules"},{"issue":"03","key":"10.1016\/j.jvacx.2023.100403_b0120","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1590\/S0104-66322005000300004","article-title":"Spray-dried chitosan microspheres cross-linked with d, l-glyceraldehyde as a potential drug delivery system: preparation and characterization","volume":"22","author":"Oliveira","year":"2005","journal-title":"Braz J Chem Eng"},{"key":"10.1016\/j.jvacx.2023.100403_b0125","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijpddr.2019.06.001","article-title":"Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles","volume":"11","author":"Sousa-Batista","year":"2019","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"5","key":"10.1016\/j.jvacx.2023.100403_b0130","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-3024.1985.tb00098.x","article-title":"A limiting dilution assay for quantifying Leishmania major in tissues of infected mice","volume":"7","author":"Titus","year":"1985","journal-title":"Parasite Immunol"},{"issue":"6","key":"10.1016\/j.jvacx.2023.100403_b0135","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3390\/md17060381","article-title":"Recent advances in chitosan-based carriers for gene delivery","volume":"17","author":"Cao","year":"2019","journal-title":"Mar Drugs"},{"issue":"1","key":"10.1016\/j.jvacx.2023.100403_b0140","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.addr.2009.08.004","article-title":"Chitosan-based formulations for delivery of DNA and siRNA","volume":"62","author":"Mao","year":"2010","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"10.1016\/j.jvacx.2023.100403_b0145","first-page":"1433","article-title":"Preparation and Characterization of Chitosan Microspheres Crossed-linked with 2, 3 - Dihydroxypropanal as a competitive Drug Delivery System","volume":"4","author":"Devraj","year":"2011","journal-title":"J Pharmacy Research"},{"key":"10.1016\/j.jvacx.2023.100403_b0150","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/07373930600564480","article-title":"Spray-Dried Chitosan Microspheres as a pDNA Carrier","volume":"24","author":"Oliveira","year":"2006","journal-title":"Drying Technol"},{"key":"10.1016\/j.jvacx.2023.100403_b0155","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11095-011-0577-4","article-title":"Promoted transfection efficiency of pDNA polyplexes-loaded biodegradable microparticles containing acid-labile segments and galactose grafts","volume":"2","author":"Chen","year":"2012","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.jvacx.2023.100403_b0160","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1208\/pt050467","article-title":"Evaluation of mucoadhesive properties of chitosan microspheres prepared by different methods","volume":"5","author":"Dhawan","year":"2004","journal-title":"AAPS Pharm Sci Tech"},{"issue":"49","key":"10.1016\/j.jvacx.2023.100403_b0165","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.1016\/j.vaccine.2008.09.061","article-title":"Functional differences between M cells and enterocytes in sampling luminal antigens","volume":"26","author":"Kyd","year":"2008","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jvacx.2023.100403_b0170","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0378-5173(99)00030-7","article-title":"Effect of chitosan on epithelial permeability and structure","volume":"182","author":"Dodane","year":"1999","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"10.1016\/j.jvacx.2023.100403_b0175","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijpharm.2010.08.020","article-title":"Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution","volume":"400","author":"Vllasaliu","year":"2010","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jvacx.2023.100403_b0180","article-title":"Crosslinking collagen constructs: Achieving cellular selectivity through modifications of physical and chemical properties","volume":"10:6911-","author":"Nair","year":"2020","journal-title":"Appl Sci"},{"issue":"10","key":"10.1016\/j.jvacx.2023.100403_b0185","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.7205\/MILMED-D-11-00150","article-title":"Safety of chitosan bandages in shellfish allergic patients","volume":"176","author":"Waibel","year":"2011","journal-title":"Mil Med"},{"issue":"28","key":"10.1016\/j.jvacx.2023.100403_b0190","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1016\/j.vaccine.2019.05.043","article-title":"Nanoencapsulated retinoic acid as a safe tolerogenic adjuvant for intranasal vaccination against cutaneous leishmaniasis","volume":"37","author":"Bezerra","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2023.100403_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101020","article-title":"Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I\/II clinical study by intradermal route in healthy subjects in India","volume":"38","author":"Momin","year":"2021","journal-title":"EClinicalMedicine"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136223001444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136223001444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T07:13:42Z","timestamp":1719990822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136223001444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":39,"alternative-id":["S2590136223001444"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2023.100403","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Crosslinked chitosan microparticles as a safe and efficient DNA carrier for intranasal vaccination against cutaneous leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2023.100403","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100403"}}